vs
null（GPRO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是再鼎医药的1.6倍（$201.7M vs $127.1M），再鼎医药同比增速更快（17.1% vs 0.4%），null自由现金流更多（$15.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 13.9%）
GoPro, Inc.是2002年由尼克·伍德曼创立的美国科技企业，最初注册名为伍德曼实验室，总部坐落于加利福尼亚州圣马特奥。该公司主营运动相机生产制造，同时还自主开发配套移动端应用与视频编辑软件。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
GPRO vs ZLAB — 直观对比
营收规模更大
GPRO
是对方的1.6倍
$127.1M
营收增速更快
ZLAB
高出16.7%
0.4%
自由现金流更多
GPRO
多$41.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
13.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $201.7M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 31.8% | 51.0% |
| 营业利润率 | -4.1% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 0.4% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GPROZLAB
| Q4 25 | $201.7M | $127.1M | ||
| Q3 25 | $162.9M | $115.4M | ||
| Q2 25 | $152.6M | $109.1M | ||
| Q1 25 | $134.3M | $105.7M | ||
| Q4 24 | $200.9M | $108.5M | ||
| Q3 24 | $258.9M | $101.8M | ||
| Q2 24 | $186.2M | $100.1M | ||
| Q1 24 | $155.5M | $87.1M |
净利润GPROZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-21.3M | $-36.0M | ||
| Q2 25 | $-16.4M | $-40.7M | ||
| Q1 25 | $-46.7M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.2M | $-41.7M | ||
| Q2 24 | $-47.8M | $-80.3M | ||
| Q1 24 | $-339.1M | $-53.5M |
毛利率GPROZLAB
| Q4 25 | 31.8% | 51.0% | ||
| Q3 25 | 35.1% | 59.5% | ||
| Q2 25 | 35.8% | 60.6% | ||
| Q1 25 | 32.1% | 63.6% | ||
| Q4 24 | 34.7% | 61.5% | ||
| Q3 24 | 35.5% | 64.1% | ||
| Q2 24 | 30.5% | 64.9% | ||
| Q1 24 | 34.1% | 61.4% |
营业利润率GPROZLAB
| Q4 25 | -4.1% | -54.6% | ||
| Q3 25 | -9.8% | -42.3% | ||
| Q2 25 | -9.2% | -50.3% | ||
| Q1 25 | -33.7% | -53.3% | ||
| Q4 24 | -19.5% | -62.6% | ||
| Q3 24 | -3.1% | -66.6% | ||
| Q2 24 | -25.0% | -76.0% | ||
| Q1 24 | -26.6% | -80.7% |
净利率GPROZLAB
| Q4 25 | — | — | ||
| Q3 25 | -13.0% | -31.2% | ||
| Q2 25 | -10.8% | -37.3% | ||
| Q1 25 | -34.8% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -3.2% | -40.9% | ||
| Q2 24 | -25.7% | -80.2% | ||
| Q1 24 | -218.1% | -61.4% |
每股收益（稀释后）GPROZLAB
| Q4 25 | $-0.06 | $-0.05 | ||
| Q3 25 | $-0.13 | $-0.03 | ||
| Q2 25 | $-0.10 | $-0.04 | ||
| Q1 25 | $-0.30 | $-0.04 | ||
| Q4 24 | $-0.22 | $-0.09 | ||
| Q3 24 | $-0.05 | $-0.04 | ||
| Q2 24 | $-0.31 | $-0.08 | ||
| Q1 24 | $-2.24 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.7M | $689.6M |
| 总债务越低越好 | $44.3M | — |
| 股东权益账面价值 | $76.5M | $715.5M |
| 总资产 | $428.0M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.58× | — |
8季度趋势，按日历期对齐
现金及短期投资GPROZLAB
| Q4 25 | $49.7M | $689.6M | ||
| Q3 25 | $152.8M | $717.2M | ||
| Q2 25 | $58.6M | $732.2M | ||
| Q1 25 | $69.6M | $757.3M | ||
| Q4 24 | $102.8M | $779.7M | ||
| Q3 24 | $130.2M | $616.1M | ||
| Q2 24 | $133.0M | $630.0M | ||
| Q1 24 | $133.7M | $650.8M |
总债务GPROZLAB
| Q4 25 | $44.3M | — | ||
| Q3 25 | $43.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $93.1M | — | ||
| Q2 24 | $92.9M | — | ||
| Q1 24 | $92.7M | — |
股东权益GPROZLAB
| Q4 25 | $76.5M | $715.5M | ||
| Q3 25 | $80.5M | $759.9M | ||
| Q2 25 | $97.9M | $791.7M | ||
| Q1 25 | $110.0M | $810.8M | ||
| Q4 24 | $151.7M | $840.9M | ||
| Q3 24 | $183.9M | $667.7M | ||
| Q2 24 | $184.7M | $704.2M | ||
| Q1 24 | $224.9M | $762.2M |
总资产GPROZLAB
| Q4 25 | $428.0M | $1.2B | ||
| Q3 25 | $538.6M | $1.2B | ||
| Q2 25 | $439.0M | $1.2B | ||
| Q1 25 | $462.5M | $1.2B | ||
| Q4 24 | $543.7M | $1.2B | ||
| Q3 24 | $661.6M | $985.3M | ||
| Q2 24 | $556.8M | $987.4M | ||
| Q1 24 | $575.8M | $988.4M |
负债/权益比GPROZLAB
| Q4 25 | 0.58× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.51× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $15.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 7.4% | -21.0% |
| 资本支出强度资本支出/营收 | 0.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-24.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流GPROZLAB
| Q4 25 | $15.6M | $-26.0M | ||
| Q3 25 | $12.2M | $-32.0M | ||
| Q2 25 | $8.8M | $-31.0M | ||
| Q1 25 | $-57.2M | $-61.7M | ||
| Q4 24 | $-25.1M | $-55.8M | ||
| Q3 24 | $-2.2M | $-26.8M | ||
| Q2 24 | $605.0K | $-42.2M | ||
| Q1 24 | $-98.4M | $-90.1M |
自由现金流GPROZLAB
| Q4 25 | $15.0M | $-26.7M | ||
| Q3 25 | $11.2M | $-35.0M | ||
| Q2 25 | $8.3M | $-33.9M | ||
| Q1 25 | $-58.5M | $-63.2M | ||
| Q4 24 | $-25.5M | $-58.4M | ||
| Q3 24 | $-4.2M | $-28.2M | ||
| Q2 24 | $-111.0K | $-42.9M | ||
| Q1 24 | $-99.4M | $-91.1M |
自由现金流率GPROZLAB
| Q4 25 | 7.4% | -21.0% | ||
| Q3 25 | 6.9% | -30.4% | ||
| Q2 25 | 5.4% | -31.1% | ||
| Q1 25 | -43.5% | -59.9% | ||
| Q4 24 | -12.7% | -53.8% | ||
| Q3 24 | -1.6% | -27.7% | ||
| Q2 24 | -0.1% | -42.9% | ||
| Q1 24 | -63.9% | -104.5% |
资本支出强度GPROZLAB
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 1.0% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.4% | 0.7% | ||
| Q1 24 | 0.6% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GPRO
| Subscription And Services | $106.3M | 53% |
| Other | $95.4M | 47% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
